TABLE 3.
Efficacy based on MRI, clinical symptoms and steroid usage at the different study time points.
| Therapeutic effect | Lose‐dose group (n = 34) | High‐dose group (n = 41) | ||||
|---|---|---|---|---|---|---|
| 3 months | 6 months | 3 months | 6 months | P1 | P2 | |
| Edema volume effective | 32 (94.1) | 27 (79.4) | 39 (95.1) | 26 (63.4) | 1.000 | 0.130 |
| Enhanced volume effective | 28 (82.4) | 23 (67.6) | 34 (82.9) | 25 (61.0) | 0.948 | 0.549 |
| Signal ratio effective | 31 (91.2) | 22 (64.7) | 31 (75.6) | 22 (53.7) | 0.067 | 0.333 |
| Clinical symptoms' effective | 0.917 | 0.752 | ||||
| Improved | 22 (64.7) | 17 (50) | 27 (65.9) | 19 (46.3) | ||
| Stable | 11 (32.4) | 9 (26.5) | 12 (29.3) | 11 (26.8) | ||
| Progression | 1 (2.9) | 8 (23.5) | 2 (4.9) | 11 (26.8) | ||
| Steroid usage' | Effective | 0.850 | 0.445 | |||
| Improved | 14 (41.2) | 11 (32.4) | 16 (39.0) | 10 (24.4) | ||
| Stable | 20 (58.7) | 18 (52.9) | 23 (56.1) | 22 (53.7) | ||
| Progression | 0 (0.0) | 5 (14.7) | 2 (4.9) | 9 (22.0) | ||
Note: Data are shown as numbers (%). P1, low‐dose group versus high‐dose group at 3 months; P2, low‐dose group versus high‐dose group at 6 months.